-- Focus on Gaining Access for European Patients in Remaining Geographies and

                    Strategic Use of Commercial Resources --
    -- Maximizes Cash Flow Opportunity Through Streamlined Model in U.S. --

-- Company Expects Restructuring to Drive Annual Cost Savings of Approximately

                                 $40 Million --
      -- Announces Preliminary Earnings Results for Second Quarter 2023 --
          -- Company to Host Conference Call Today at 5:00 p.m. EDT --

DUBLIN, Ireland and BRIDGEWATER, N.J., July 18, 2023 (GLOBE NEWSWIRE) -- Amarin
Corporation plc (NASDAQ: AMRN) today announced that it has initiated an
organizational restructuring program to right-size and strengthen the Company to
enhance shareholder value.
Over the last several months, the new Amarin Board of Directors and senior
management team have conducted a comprehensive review of the business.
VASCEPA(®)/VAZKEPA(®) is supported by a wealth of clinical data and backed by
strong science that can benefit patients around the world. Amarin continues to
generate revenue in the U.S. and maintains a strong cash position. However, the
restructuring announced today reflects the need for a thoughtful and significant
change in strategy given the Company's size, resources and challenging operating
environment. The Company expects these actions will reduce operating costs by
approximately $40 million annually.
Amarin's refocused strategic priorities and restructuring plan focuses on three
core areas:

  * Maximizing U.S. Cash Flow Through Streamlined Model: Amarin will maintain
    VASCEPA as a cost-effective option to generics while implementing a
    reduction in force of all U.S. sales force positions and approximately 30%
    of non-sales roles. Amarin will retain its managed care and trade
    organization to support these efforts. The Company will continue to explore
    innovative approaches to driving revenue as well as the timing of an

authorized generic version of VASCEPA to maintain its leadership position in

    the icosapent ethyl (IPE) market.
  * European Redesign: Amarin will redesign its commercial infrastructure in
    Europe to better align with pricing and reimbursement status, commercial
    potential and progress to date, as well as streamline certain cross-
    geographic functions and better leverage learnings across countries. In
    addition, Amarin will continue to advance its pricing and reimbursement
    activities to drive access in remaining geographies, including those where
    progress has been delayed.
  * Expanding Upon International Partnerships: Amarin will work on generating
    revenue from its partnerships in key international markets, including
    Canada, MENA, China and Australia / New Zealand, and will continue to
    explore additional partnerships.

"A thorough review confirmed our belief in the inherent value of Amarin and the
need for change when it comes to managing the business for value creation," said
Odysseas Kostas, M.D., and Chairman of the Board. "The actions we have taken
since joining the Board reflect our ongoing efforts to turn around the company.
The organizational restructuring and our new CEO hire announced today will
support those strategic efforts. Our focus continues to be bringing
VASCEPA/VAZKEPA to high-risk patients and generating value for Amarin
shareholders as we execute against this strategy."
"We are grateful for the efforts and commitments of our impacted colleagues who
have worked tirelessly to advance our mission in the U.S. and globally," said
Aaron Berg, Amarin's Interim President and CEO. "These are difficult, but
necessary decisions to best position Amarin for the future and ensure we can
give millions of patients globally the opportunity to access VASCEPA/VAZKEPA. We
maintain strong conviction around VASCEPA/VAZKEPA, which is supported by a
wealth of clinical data and backed by strong science, particularly the results
of the REDUCE-IT trial and its impact on cardiovascular outcomes, which clearly
underscore the product's value in addressing a significant unmet need to reduce
major adverse cardiovascular events in high-risk patients."
Preliminary Q2 2023 Earnings Results
In connection with today's announcement, Amarin also announced preliminary
unaudited financial results for the second quarter of 2023, including product
revenue of approximately $65 million compared to $85 million in the first
quarter of 2023. For the quarter, the Company had positive cash flow of $9
million, which includes a $5 million milestone payment following the recent VHTG
regulatory approval in China. The second quarter end cash position was $313
million versus $304 million at the end of the first quarter. Further details
will be discussed on today's conference call.
"In the second quarter, we maintained our U.S. prescription volume for VASCEPA
and our overall cash position is positive," Mr. Berg said. "However, our product
revenue was impacted by increasing net pricing pressure and other inter-quarter
variability in the U.S. and we also saw slower than expected revenue
materialization and pricing and reimbursement access in Europe. As a result, we
are taking decisive and significant actions to realign our business, which will
maximize our strong cash position while putting us on the right path to enhance
shareholder value."
Conference Call and Webcast Information
Amarin will host a conference call on July 18, 2023, at 5:00 p.m. EDT to discuss
this announcement and the Company's preliminary financial results. The
conference call can be accessed on the investor relations section of the
Company's website at www.amarincorp.com, or via telephone by dialing
888-506-0062 within the United States, 973-528-0011 from outside the United
States, and referencing conference ID 897730. A replay of the call will be made
available for a period of one week following the conference call. To listen to a
replay of the call, dial 877-481-4010 from within the United States and
919-882-2331 from outside of the United States, and reference conference ID
48709. A replay of the call will also be available through the Company's website
shortly after the call.
In light of the call scheduled for today, Amarin will release its full second
quarter 2023 financial results on August 2, 2023, but will not hold a conference
call at that time.
About Amarin
Amarin is an innovative pharmaceutical company leading a new paradigm in
cardiovascular disease management. Amarin is committed to increasing the
scientific understanding of the cardiovascular risk that persists beyond
traditional therapies and advancing the treatment of that risk for patients
worldwide. Amarin has offices in Bridgewater, New Jersey in the United States,
Dublin in Ireland, Zug in Switzerland, and other countries in Europe as well as
commercial partners and suppliers around the world.
Forward-Looking Statements
This press release contains forward-looking statements, within the meaning of
U.S. securities laws, including, but not limited to, expectations regarding
Amarin's financial performance, metrics, and initiatives, including its 2023
revenues, operating expenses, supply purchases, negotiations and settlements,
product prescriptions and managed care coverage, continued savings from cost-
cutting initiatives that is currently exceeding initial targets, and Amarin's
overall ability to continue to deliver stable revenues and cash position from
its U.S. business; beliefs about the timing and outcome of international
commercial partnerships, regulatory filings, reviews, recommendations,
approvals, and related reimbursement decisions and commercial launches of
VASCEPA/VAZKEPA outside of the U.S.; beliefs that Amarin's current resources are
sufficient to fund projected operations; and beliefs about the overall world-
wide market potential and success of VASCEPA/VAZKEPA generally. These forward-
looking statements are not promises or guarantees and involve substantial risks
and uncertainties. A list and description of these risks, uncertainties and
other risks associated with an investment in Amarin can be found in Amarin's
filings with the U.S. Securities and Exchange Commission, including Amarin's
most recent quarterly report on Form 10-Q for the quarter ended March 31, 2023.
Existing and prospective investors are cautioned not to place undue reliance on
these forward-looking statements, which speak only as of the date they are made.
Amarin undertakes no obligation to update or revise the information contained in
its forward-looking statements, whether as a result of new information, future
events or circumstances or otherwise. Amarin's forward-looking statements do not
reflect the potential impact of significant transactions the company may enter
into, such as mergers, acquisitions, dispositions, joint ventures or any
material agreements that Amarin may enter into, amend or terminate.
Availability of Other Information About Amarin
Investors and others should note that Amarin communicates with its investors and
the public using the company website (www.amarincorp.com), the investor
relations website (amarincorp.gcs-web.com), including but not limited to
investor presentations and investor FAQs, U.S. Securities and Exchange
Commission filings, press releases, public conference calls and webcasts. The
information that Amarin posts on these channels and websites could be deemed to
be material information. As a result, Amarin encourages investors, the media,
and others interested in Amarin to review the information that is posted on
these channels, including the investor relations website, on a regular basis.
This list of channels may be updated from time to time on Amarin's investor
relations website and may include social media channels. The contents of
Amarin's website or these channels, or any other website that may be accessed
from its website or these channels, shall not be deemed incorporated by
reference in any filing under the Securities Act of 1933.
Amarin Contact Information
Investor Inquiries:
Jordan Zwick
Amarin Corporation plc
IR@amarincorp.com??
Media Inquiries:
Mark Marmur
Amarin Corporation plc
PR@amarincorp.com
Â